康柏西普单次玻璃体内注射对糖尿病黄斑水肿患者黄斑形态与功能的影响

目的　观察糖尿病黄斑水肿（diabetic macular edema，DME）患者接受康柏西普单次玻璃体内注射治疗后黄斑形态与功能的恢复情况。方法　回顾性分析23例（25眼）DME患者临床资料。按照是否接受康柏西普玻璃体内注射治疗分为治疗组和对照组。观察并比较两组患者观察起点与终点（治疗组术前与术后1个月比较，对照组入组与随访观察1个月比较）最佳矫正视力（best corrected visual acuity,BCVA）、黄斑中心凹视网膜厚度（central retinal thickness,CRT）和微视野计检测的视网膜光敏感度等。结果　治疗组观察起点CRT为(448.73±193.25)μm，观察终点CRT为（300.60±74.93）μm，二者比较差异有统计学意义(t=2.768，P=0.010)。所有患者经康柏西普玻璃体内注射治疗后均无手术并发症发生。所有研究对象4°内注视点均>75%，治疗组和对照组4°与8°的视野视网膜光敏感度观察终点与观察起点比较差异均无统计学意义（均为P>0.05），两组间4°与8°视野视网膜光敏感度在观察起点及观察终点比较差异均无统计学意义（均为P>0.05）；两组12°平均视网膜光敏感度比较差异有统计学意义（P=0.011）。结论　玻璃体内单次注射康柏西普治疗DME安全有效，能够有效地减轻黄斑水肿及提高视力，形态学恢复早于功能学恢复。

Changes in macular morphology and function of diabetic macular edema after intravitreal injection of Conbercept

Objective　To observe the morphological and functional recovery of diabetic macular edema (DME) patients after intravitreal injection of conbercept (IVC).Methods　A retrospesctive study was analyzed in 23 patients (25 eyes) with DME. The patients were divided into two groups according to whether they received IVC or not: treatment group and control group. The best corrected visual acuity (BCVA), central retinal thickness (CRT) of macular fovea and measured by microperimetry were measuredbefore and 1 month after IVC treatment in the treatment group and before and 1 month after observation in the control group.Results　In the treatment group, the CRTat the observation starting point was (448.73±193.25) μm, while (300.60±74.93) μm at the observation end point, and the difference between the two was statistically significant Significance (t=2.768, P=0.010).All patients had no surgical complications after IVC treatment. The gaze point of all subjects within 4° was >75%, and there was no statistically significant difference inthe 4° and 8° field visual retinal photosensitivitybetween the observation end pointand the observation start point of both groups (all P>0.05). There was no statistically significant difference between the two groups at the starting point and end point of observation (both P>0.05). The difference in average visual retinal photosensitivity between the two groups at 12° field was statistically significant (P=0.011).Conclusion　Single intravitreal injection of Compaqip is safe and effective in the treatment of DME, and can effectively reduce macular edema, improve vision, and morphological recovery is earlier than functional recovery.